The Dementia Consortium will provide funding, resources and expertise to both increase the number of, and capitalise upon, new drug targets emerging from across the academic sector that hold promise of bringing patient benefit.
The Dementia Consortium members are Alzheimer’s Research UK, technology transfer and drug discovery experts Evotec and the pharmaceutical companies, Abbvie, Astex, Eisai, Johnson & Johnson, Lilly and MSD.
For target validation and drug discovery projects, please apply via the Dementia Consortium.
The duration and amount will be determined at full application stage. We anticipate typical projects to be up to two years in duration and cost £100,000-£250,000. There is a notional limit of £500,000 for exceptional cases.